Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
